Stockreport

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Cybin Inc. Common Shares  (CYBN) 
PDF - The Company is evaluating non-hallucinogenic dosing of CYB005 preclinical candidate molecules for the treatment of CNS disorders -- Cybin’s sector-leading intellectual [Read more]